ReviewJournal of comparative effectiveness research2020
Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019.
Review in Journal of comparative effectiveness research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Observational
- Pulmonary Delivery of Anti-microRNA Oligonucleotide and Glycyrrhizic Acid Using Ternary Peptide Micelles for the Treatment of Acute Lung Injury.Biomaterials research · 2024Article
- Relationship between glucocorticoids and viral load during the Omicron wave in mainland China.Virology journal · 2023Article
- Article
- Effects of dexamethasone use on viral clearance among patients with COVID-19: a multicenter cohort study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Article
- Relationship between steroid use and superinfections in SARS-CoV-2 patients. A systematic review and meta-analysis.Infection ecology & epidemiology · 2023Review
- Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment.Process biochemistry (Barking, London, England) · 2022Article
- Pathogenesis of pneumonia and acute lung injury.Clinical science (London, England : 1979) · 2022Review
- Dexamethasone for Severe COVID-19: How Does It Work at Cellular and Molecular Levels?International journal of molecular sciences · 2021Review
- Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics.International journal of molecular sciences · 2021Review
- Possible respiratory syncytial virus infection presenting as diffuse alveolar hemorrhage in an elderly treated with systemic corticosteroid: A case report.Respiratory medicine case reports · 2021Article
- The Efficacy of High-Dose Pulse Therapy vs. Low-Dose Intravenous Methylprednisolone on Severe to Critical COVID-19 Clinical Outcomes: A Randomized Clinical Trial.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dexamethasone was shown to decrease the mortality in coronavirus disease-2019 (COVID-19) recently. Use of corticosteroids was harmful in other coronavirus infections previously. WHO recommended against routine use of corticosteroids in COVID-19. In view of these, we reviewed the evidence about the use of corticosteroids in virus-induced acute respiratory distress syndrome (ARDS). Corticosteroids are beneficial in ARDS regardless of etiology. However, they increased the mortality rate in influenza-associated ARDS. In SARS and the Middle East respiratory syndrome, corticosteroids increased the mortality, delayed the viral clearance and increased the length of hospital stay. In the case of COVID-19, the available evidence from retrospective and observational studies is inconclusive about the corticosteroid use. Low-dose therapies appear to be effective. Evidence from a randomized control study found dexamethasone is effective in decreasing mortality in severe COVID-19 cases. More studies are needed to validate the benefit of corticosteroids in COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.